Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer

Figures & data

Table I. Patient characteristics.

Median age, years (range)	67 (29–75)
Gender: male/female	36/6
PS: 0/1	18/24
Weight loss >5%/<5%	5/37
Histology
Adenocarcinoma	12
Squamous cell carcinoma	26
Unclassified	4
Stage of disease: IIIA/IIIB	8/34

PS, performance status.

Figure 1. Overall survival curve from the initiation of docetaxel, cisplatin, and concurrent radiation.

Figure 2. Progression-free survival curve from the initiation of docetaxel, cisplatin, and concurrent radiation.

Table II. Characteristics of patients who were progression-free more than two years.

Survival (year)	Status	PS	H-J	Age
2.1	death due to bacterial pneumonia			51
3.8	death due to gall bladder cancer			63
4.9	death due to bacterial pneumonia			72
5.9	alive	0	1	72
6.0	alive	0	1	70
6.1	alive	0	1	72
6.2	death due to fungal pneumonia			74
6.3	alive	0	1	72
6.4	alive	0	1	66
6.5	alive	1	3	78
6.6	alive with secondary lung cancer	0	1	61
6.8	alive	0	1	77
7.0	alive	0	1	36
7.1	alive	0	3	74

PS, performance status; H-J, Hugh-Jones classification score, and age were at the time of last follow-up or death.

Table III. Dose intensities for cisplatin, docetaxel and radiotherapy.

	Cisplatin^a (%)	Docetaxel^a (%)	Radiation^b (%)
Long survivors without progression-free (n = 14)	88.9 ± 14.4	87.3 ± 16.3	91.2 ± 13.9
Others (n = 28)	85.6 ± 21.7	85.5 ± 22.1	90.3 ± 13.5
p	0.022	0.105	0.673

^aAdministered drug dose (mg/m²/week)/projected drug dose (mg/m²/week).

^bActual radiation dose (Gy/week)/projected radiation dose (Gy/week).